Reportedly, driven by products such as the Nexovar oral anti-cancer medication, the antiplatelet AspirinCardio and Yaz oral contraceptive pill, Bayer Schering Pharma’s sales in Asia Pacific, which excludes Japan, grew 13% to EUR1.04bn in 2009, representing 10% of its global sales.
Bayer Schering Pharma said that it intends to boost its sales in the long run by above market average growth rates in India and has launched growth strategy in India at its annual Asia Pacific press conference in Singapore.
Alok Kanti, head of Asia Pacific at Bayer Schering Pharma, said: “Our aim is to become stronger in the market and to have the support to be able to grow above the market and that is what we focus on.”
Bayer Schering Pharma is presently considering a specific acquisition in India and is aiming at a sixfold increase in sales in Vietnam by 2015 and a tripling of the workforce there. The company has set a goal to become one of the top three pharmaceutical groups in South Korea by 2013, with plans to increase the staff there by 20%, and among the top 10 pharma groups in India by 2015.
Richard Nieman, Asia Pacific head of global medical affairs at Bayer Schering Pharma, said that the company plans to integrate its Asia product development with the US and Europe, so that it can release products in Asia simultaneously along with the company’s traditional markets.